Literature DB >> 27296355

Multicentric Castleman disease: Where are we now?

Hao-Wei Wang1, Stefania Pittaluga1, Elaine S Jaffe2.   

Abstract

Multicentric Castleman disease (MCD) encompasses a spectrum of conditions that give rise to overlapping clinicopathological manifestations. The fundamental pathogenetic mechanism involves dysregulated cytokine activity that causes systemic inflammatory symptoms as well as lymphadenopathy. The histological changes in lymph nodes resemble in part the findings originally described in the unicentric forms Castleman disease, both hyaline vascular and plasma cell variants. In MCD caused by Kaposi sarcoma-associated herpesvirus/human herpesvirus-8 (KSHV/HHV8), the cytokine over activity is caused by viral products, which can also lead to atypical lymphoproliferations and potential progression to lymphoma. In cases negative for KSHV/HHV8, so-called idiopathic MCD, the hypercytokinemia can result from various mechanisms, which ultimately lead to different constellations of clinical presentations and varied pathology in lymphoid tissues. In this article, we review the evolving concepts and definitions of the various conditions under the eponym of Castleman disease, and summarize current knowledge regarding the histopathology and pathogenesis of lesions within the MCD spectrum. Published by Elsevier Inc.

Entities:  

Keywords:  Acquired immune deficiency syndrome; Castleman disease; Human herpesvirus type-8; Interleukin-6; Kaposi sarcoma-associated herpesvirus; TAFRO syndrome

Mesh:

Year:  2016        PMID: 27296355      PMCID: PMC5003700          DOI: 10.1053/j.semdp.2016.05.006

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  127 in total

1.  Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins.

Authors:  S Ishido; C Wang; B S Lee; G B Cohen; J U Jung
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Viral interferon regulatory factor 1 of Kaposi's sarcoma-associated herpesvirus binds to p53 and represses p53-dependent transcription and apoptosis.

Authors:  T Seo; J Park; D Lee; S G Hwang; J Choe
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Kaposi's sarcoma-associated herpesvirus viral IFN regulatory factor 3 stabilizes hypoxia-inducible factor-1 alpha to induce vascular endothelial growth factor expression.

Authors:  Young C Shin; Chul-Hyun Joo; Michaela U Gack; Hye-Ra Lee; Jae U Jung
Journal:  Cancer Res       Date:  2008-03-15       Impact factor: 12.701

4.  Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.

Authors:  Mark N Polizzotto; Thomas S Uldrick; Victoria Wang; Karen Aleman; Kathleen M Wyvill; Vickie Marshall; Stefania Pittaluga; Deirdre O'Mahony; Denise Whitby; Giovanna Tosato; Seth M Steinberg; Richard F Little; Robert Yarchoan
Journal:  Blood       Date:  2013-10-30       Impact factor: 22.113

5.  The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor.

Authors:  Akrit Sodhi; Risa Chaisuparat; Jiadi Hu; Amanda K Ramsdell; Brendan D Manning; Edward A Sausville; Earl T Sawai; Alfredo Molinolo; J Silvio Gutkind; Silvia Montaner
Journal:  Cancer Cell       Date:  2006-08       Impact factor: 31.743

Review 6.  FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease.

Authors:  Albert Deisseroth; Chia-Wen Ko; Lei Nie; Jeanne F Zirkelbach; Liang Zhao; Julie Bullock; Nitin Mehrotra; Pedro Del Valle; Haleh Saber; Christopher Sheth; Brenda Gehrke; Robert Justice; Ann Farrell; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2015-01-19       Impact factor: 12.531

7.  Clinical implications of idiopathic multicentric castleman disease among Japanese: a report of 28 cases.

Authors:  Masaru Kojima; Naoya Nakamura; Norihumi Tsukamoto; Yoshiro Otuski; Kazuhiko Shimizu; Hideaki Itoh; Satsuki Kobayashi; Hiroshi Kobayashi; Takuhei Murase; Nobuhide Masawa; Makoto Kashimura; Shigeo Nakamura
Journal:  Int J Surg Pathol       Date:  2008-05-21       Impact factor: 1.271

8.  KSHV- and EBV-associated germinotropic lymphoproliferative disorder: a rare lymphoproliferative disease of HIV patient with plasmablastic morphology, indolent course and favourable response to therapy.

Authors:  Antonio D'Antonio; D'Antonio Antonio; Amedeo Boscaino; Boscaino Amedeo; Maria Addesso; Addesso Maria; Miguel Angel Piris; Piris Miguel Angel; Oscar Nappi; Nappi Oscar
Journal:  Leuk Lymphoma       Date:  2007-07

9.  Modulation of p27(Kip1) levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus.

Authors:  D J Mann; E S Child; C Swanton; H Laman; N Jones
Journal:  EMBO J       Date:  1999-02-01       Impact factor: 11.598

Review 10.  POEMS syndrome: 2014 update on diagnosis, risk-stratification, and management.

Authors:  Angela Dispenzieri
Journal:  Am J Hematol       Date:  2014-02       Impact factor: 10.047

View more
  35 in total

Review 1.  Extrafollicular activities: perspectives on HIV infection, germinal center-independent maturation pathways, and KSHV-mediated lymphoproliferation.

Authors:  Jennifer Totonchy
Journal:  Curr Opin Virol       Date:  2017-08-03       Impact factor: 7.090

2.  International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; Thomas S Uldrick; Adam Bagg; Dale Frank; David Wu; Gordan Srkalovic; David Simpson; Amy Y Liu; David Menke; Shanmuganathan Chandrakasan; Mary Jo Lechowicz; Raymond S M Wong; Sheila Pierson; Michele Paessler; Jean-François Rossi; Makoto Ide; Jason Ruth; Michael Croglio; Alexander Suarez; Vera Krymskaya; Amy Chadburn; Gisele Colleoni; Sunita Nasta; Raj Jayanthan; Christopher S Nabel; Corey Casper; Angela Dispenzieri; Alexander Fosså; Dermot Kelleher; Razelle Kurzrock; Peter Voorhees; Ahmet Dogan; Kazuyuki Yoshizaki; Frits van Rhee; Eric Oksenhendler; Elaine S Jaffe; Kojo S J Elenitoba-Johnson; Megan S Lim
Journal:  Blood       Date:  2017-01-13       Impact factor: 22.113

3.  Unraveling Castleman: progress in a complex process.

Authors:  Kieron Dunleavy
Journal:  Blood       Date:  2017-03-23       Impact factor: 22.113

4.  Fever and generalised lymphadenopathy in an HIV-positive patient: a diagnostic challenge.

Authors:  Bernardo Neves; Pedro Raimundo; Pedro Farinha
Journal:  BMJ Case Rep       Date:  2017-08-16

5.  TAFRO syndrome: A case report and review of the literature.

Authors:  Tieying Hou; Jaspreet Dhillon; Wenbin Xiao; Elaine S Jaffe; Amy M Sands; Vishala Neppalli; George Deeb; Nan Zhang
Journal:  Hum Pathol (N Y)       Date:  2017-04-21

Review 6.  Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease.

Authors:  Kathryn Lurain; Robert Yarchoan; Thomas S Uldrick
Journal:  Hematol Oncol Clin North Am       Date:  2018-02       Impact factor: 3.722

7.  A rare case of multicentric castleman's disease transforms into multiple myeloma and its successful treatment.

Authors:  Dan Yang; Xuan Zhou; Youcai Zhao; Shibin Cao; Ailing Su; Xuezhong Zhang; Yanli Xu; Xiuqun Zhang
Journal:  Cancer Biol Ther       Date:  2018-04-30       Impact factor: 4.742

8.  Histologic and Laboratory Characteristics of Symptomatic and Asymptomatic Castleman Disease in the Pediatric Population.

Authors:  Karen M Chisholm; Mark D Fleming
Journal:  Am J Clin Pathol       Date:  2020-05-05       Impact factor: 2.493

Review 9.  Lipids, lipid metabolism and Kaposi's sarcoma-associated herpesvirus pathogenesis.

Authors:  Lu Dai; Zhen Lin; Wei Jiang; Erik K Flemington; Zhiqiang Qin
Journal:  Virol Sin       Date:  2017-10-10       Impact factor: 4.327

Review 10.  KSHV/HHV8-mediated hematologic diseases.

Authors:  Ethel Cesarman; Amy Chadburn; Paul G Rubinstein
Journal:  Blood       Date:  2022-02-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.